Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PRDX3

Gene summary for PRDX3

Gene summary.

Gene information	Species	Human
	Gene symbol	PRDX3
	Gene ID	10935
	Gene name	peroxiredoxin 3
	Gene Alias	AOP-1
	Cytomap	10q26.11
	Gene Type	protein-coding
	GO ID	GO:0000003
	UniProtAcc	P30048

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
10935	PRDX3	HTA11_1938_2000001011	Human	Colorectum	AD	6.49e-09	6.01e-01	-0.0811
10935	PRDX3	HTA11_78_2000001011	Human	Colorectum	AD	1.02e-05	3.19e-01	-0.1088
10935	PRDX3	HTA11_347_2000001011	Human	Colorectum	AD	1.02e-10	3.72e-01	-0.1954
10935	PRDX3	HTA11_696_2000001011	Human	Colorectum	AD	1.41e-02	1.70e-01	-0.1464
10935	PRDX3	HTA11_1391_2000001011	Human	Colorectum	AD	2.21e-03	3.28e-01	-0.059
10935	PRDX3	HTA11_7862_2000001011	Human	Colorectum	AD	1.55e-04	4.17e-01	-0.0179
10935	PRDX3	HTA11_866_3004761011	Human	Colorectum	AD	7.05e-08	3.83e-01	0.096
10935	PRDX3	HTA11_4255_2000001011	Human	Colorectum	SER	6.14e-06	5.64e-01	0.0446
10935	PRDX3	HTA11_8622_2000001021	Human	Colorectum	SER	4.38e-02	3.56e-01	0.0528
10935	PRDX3	HTA11_6801_2000001011	Human	Colorectum	SER	4.51e-12	9.89e-01	0.0171
10935	PRDX3	HTA11_7696_3000711011	Human	Colorectum	AD	2.75e-08	2.53e-01	0.0674
10935	PRDX3	HTA11_7469_2000001011	Human	Colorectum	AD	3.77e-04	6.06e-01	-0.0124
10935	PRDX3	HTA11_6818_2000001021	Human	Colorectum	AD	3.33e-05	3.00e-01	0.0588
10935	PRDX3	HTA11_99999970781_79442	Human	Colorectum	MSS	8.78e-29	6.97e-01	0.294
10935	PRDX3	HTA11_99999965062_69753	Human	Colorectum	MSI-H	1.16e-05	1.04e+00	0.3487
10935	PRDX3	HTA11_99999965104_69814	Human	Colorectum	MSS	3.99e-12	5.90e-01	0.281
10935	PRDX3	HTA11_99999971662_82457	Human	Colorectum	MSS	1.17e-17	5.71e-01	0.3859
10935	PRDX3	HTA11_99999974143_84620	Human	Colorectum	MSS	2.03e-03	2.35e-01	0.3005
10935	PRDX3	AEH-subject1	Human	Endometrium	AEH	4.90e-06	-2.75e-01	-0.3059
10935	PRDX3	AEH-subject2	Human	Endometrium	AEH	1.50e-08	-2.73e-01	-0.2525

Page: 1 2 3 4 5 6 7 8 9

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00447067	Oral cavity	OSCC	multi-multicellular organism process	105/7305	220/18723	5.05e-03	1.97e-02	105
GO:009875418	Oral cavity	OSCC	detoxification	75/7305	152/18723	5.99e-03	2.28e-02	75
GO:0006979110	Oral cavity	LP	response to oxidative stress	181/4623	446/18723	5.74e-14	6.10e-12	181
GO:2000116110	Oral cavity	LP	regulation of cysteine-type endopeptidase activity	109/4623	235/18723	3.16e-13	2.91e-11	109
GO:0043281110	Oral cavity	LP	regulation of cysteine-type endopeptidase activity involved in apoptotic process	99/4623	209/18723	7.89e-13	6.68e-11	99
GO:0052547110	Oral cavity	LP	regulation of peptidase activity	177/4623	461/18723	3.01e-11	2.00e-09	177
GO:0052548110	Oral cavity	LP	regulation of endopeptidase activity	164/4623	432/18723	4.33e-10	2.20e-08	164
GO:0000302110	Oral cavity	LP	response to reactive oxygen species	95/4623	222/18723	2.23e-09	9.98e-08	95
GO:0042542110	Oral cavity	LP	response to hydrogen peroxide	68/4623	146/18723	6.95e-09	2.81e-07	68
GO:004315418	Oral cavity	LP	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	43/4623	78/18723	8.35e-09	3.31e-07	43
GO:0062197110	Oral cavity	LP	cellular response to chemical stress	130/4623	337/18723	8.94e-09	3.52e-07	130
GO:200011719	Oral cavity	LP	negative regulation of cysteine-type endopeptidase activity	46/4623	86/18723	9.22e-09	3.61e-07	46
GO:0051348110	Oral cavity	LP	negative regulation of transferase activity	106/4623	268/18723	4.60e-08	1.61e-06	106
GO:0034599110	Oral cavity	LP	cellular response to oxidative stress	110/4623	288/18723	2.19e-07	6.65e-06	110
GO:0010563110	Oral cavity	LP	negative regulation of phosphorus metabolic process	153/4623	442/18723	1.47e-06	3.53e-05	153
GO:0045936110	Oral cavity	LP	negative regulation of phosphate metabolic process	152/4623	441/18723	2.10e-06	4.77e-05	152
GO:005188116	Oral cavity	LP	regulation of mitochondrial membrane potential	36/4623	74/18723	6.85e-06	1.34e-04	36
GO:0045861110	Oral cavity	LP	negative regulation of proteolysis	122/4623	351/18723	1.32e-05	2.34e-04	122
GO:005109213	Oral cavity	LP	positive regulation of NF-kappaB transcription factor activity	61/4623	152/18723	1.82e-05	3.11e-04	61
GO:0030099110	Oral cavity	LP	myeloid cell differentiation	130/4623	381/18723	1.94e-05	3.27e-04	130

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PRDX3

SNV

Missense_Mutation

rs548327727

c.604N>A

p.Asp202Asn

p.D202N

P30048

protein_coding

deleterious(0.03)

probably_damaging(0.994)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PRDX3

SNV

Missense_Mutation

c.301N>T

p.Pro101Ser

p.P101S

P30048

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-CK-4951-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

PRDX3

SNV

Missense_Mutation

rs548327727

c.604G>A

p.Asp202Asn

p.D202N

P30048

protein_coding

deleterious(0.03)

probably_damaging(0.994)

TCGA-AX-A2HC-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

paclitaxel

PRDX3

SNV

Missense_Mutation

rs751585321

c.640C>T

p.Arg214Cys

p.R214C

P30048

protein_coding

deleterious(0.04)

benign(0.074)

TCGA-B5-A0JZ-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

PRDX3

SNV

Missense_Mutation

rs779344159

c.361G>A

p.Glu121Lys

p.E121K

P30048

protein_coding

tolerated(0.11)

possibly_damaging(0.79)

TCGA-BS-A0UF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

PRDX3

SNV

Missense_Mutation

novel

c.223N>G

p.Thr75Ala

p.T75A

P30048

protein_coding

deleterious(0.02)

possibly_damaging(0.878)

TCGA-D1-A1NY-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Chemotherapy

carboplatin

PRDX3

SNV

Missense_Mutation

novel

c.443G>T

p.Arg148Ile

p.R148I

P30048

protein_coding

deleterious(0)

possibly_damaging(0.859)

TCGA-E6-A1LX-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

PRDX3

SNV

Missense_Mutation

novel

c.221N>A

p.Gly74Asp

p.G74D

P30048

protein_coding

deleterious(0.03)

probably_damaging(0.993)

TCGA-E6-A2P9-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

PRDX3

SNV

Missense_Mutation

rs772428160

c.128N>C

p.Leu43Ser

p.L43S

P30048

protein_coding

tolerated(0.21)

benign(0.013)

TCGA-EO-A3AY-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

PRDX3

SNV

Missense_Mutation

novel

c.541C>A

p.Leu181Ile

p.L181I

P30048

protein_coding

tolerated(1)

benign(0.005)

TCGA-FI-A2D5-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatinum

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1